Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CoV2 preS dTM + AS03
- Development stage
- Phase 2
- Lead developer
- Parent
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
**CoV2 preS dTM + AS03** is a recombinant protein subunit vaccine for prevention of COVID-19. It combines a recombinant prefusion-stabilized spike protein (preS dTM) of SARS-CoV-2, produced using a baculovirus expression vector system in insect cells, with AS03, a proprietary oil-in-water adjuvant composed of α-tocopherol, squalene, and polysorbate 80. The preS dTM protein is designed for increased stability and immunogenicity through specific mutations (including proline substitutions and deletion of the transmembrane domain with addition of a T4 foldon trimerization domain). AS03 enhances immune responses, promoting both neutralizing antibody production and cellular immune activation against spike protein, with demonstrated protection in animal models and humans. CoV2 preS dTM + AS03 has been evaluated in clinical trials for efficacy, safety, and immunogenicity as a primary immunization and booster against COVID-19, and is manufactured in both monovalent (ancestral and variant B.1.351 spike) and bivalent formulations[1][2][3][4].
- Brand names
- VidPrevtyn Beta
- Other names
- SARS-CoV-2 Spike Protein Vaccine adjuvanted with AS03SARS-CoV2 Spike Protein Vaccine adjuvanted with AS03SARS-CoV 2 Spike Protein Vaccine adjuvanted with AS03CoV2 preS dTM + AS03
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on CoV2 preS dTM + AS03.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CoV2 preS dTM + AS03.